Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C33H39N2O2 |
| Molecular Weight | 495.675 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C2=CC3=C(CCCC(=C3)C(=O)NC4=CC=C(C[N+](C)(C)C5CCOCC5)C=C4)C=C2
InChI
InChIKey=XNHZXMPLVSJQFK-UHFFFAOYSA-O
InChI=1S/C33H38N2O2/c1-24-7-11-27(12-8-24)28-14-13-26-5-4-6-29(22-30(26)21-28)33(36)34-31-15-9-25(10-16-31)23-35(2,3)32-17-19-37-20-18-32/h7-16,21-22,32H,4-6,17-20,23H2,1-3H3/p+1
TAK-779 is a selective antagonist of CCR5 receptor, which was initially developed by Takeda for the treatment of HIV infection. However, the development was terminated due to poor oral bioavailability. Also, TAK-779 demonstrated the ability to protect the brain against focal cerebral ischemia in mice.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P51681|||O14700|||O14708 Gene ID: 1234.0 Gene Symbol: CCR5 Target Organism: Homo sapiens (Human) |
1.1 nM [Ki] | ||
Target ID: CHEMBL274 |
1.4 nM [IC50] | ||
Target ID: CHEMBL4015 |
27.0 nM [IC50] | ||
Target ID: CHEMBL378 |
1.2 nM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779. | 2015-04 |
|
| Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling. | 2014-01-07 |
|
| Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model. | 2011-07 |
|
| TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice. | 2002-07 |
|
| TAK-779 (Takeda). | 2001-03 |
|
| A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. | 1999-05-11 |
Sample Use Guides
In a mouse model of ischemic brain injury, TAK-779 (25 or 250 ng in 5 uL) was administered by intracerebroventricular injection (1.0 mm lateral, 0.5 mm posterior, 3.0 mm ventral to bregma) at 10 minutes before MCA occlusion, or by intravenous injection (5 ug/100 uL per 20 g body weight).
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20180974
Created by
admin on Mon Mar 31 23:42:26 GMT 2025 , Edited by admin on Mon Mar 31 23:42:26 GMT 2025
|
PRIMARY | |||
|
183790
Created by
admin on Mon Mar 31 23:42:26 GMT 2025 , Edited by admin on Mon Mar 31 23:42:26 GMT 2025
|
PRIMARY | |||
|
RN3X97C29H
Created by
admin on Mon Mar 31 23:42:26 GMT 2025 , Edited by admin on Mon Mar 31 23:42:26 GMT 2025
|
PRIMARY | |||
|
263765-56-6
Created by
admin on Mon Mar 31 23:42:26 GMT 2025 , Edited by admin on Mon Mar 31 23:42:26 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
